Cabozantinib + abiraterone in management of chemo-naive mCRPC

According to a media release issued earlier today by Exelixis, the company has initiated a randomized Phase II clinical trial of cabozantinib + abiraterone + prednisone (CAP) versus abiraterone + prednisone (AP) in chemotherapy-naive men with metastatic, castration-resistant prostate cancer (mCRPC).

This trial  is designed to enroll about 280 patients and will be conducted at about 50 different sites in North America. Patients who are randomized to the CAP arm of the trial will  receive standard doses of abiraterone + prednisone and one of three possible doses of cabozantinib: 40 mg daily, 20 mg daily, or 20 mg every other day. Presumably about 70 men will be randomized to each of these three arms of the trial and the remaining 70 patients will receive abiraterone + prednisone alone.

The primary endpoint of the trial will be radiographic progression-free survival. For more information about this trial, please see the web site.

This is yet another trial that will help us to understand the potential of therapy combinations in the management of castration-resistant prostate cancer — always assume that anyone is going to be able to afford to cover the costs of such combination therapies.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: